Esperion Therapeutics, Inc.ESPRNASDAQ
LOADING
|||
Operating Income Growth Under Pressure
Trending lower, below historical average, strong compound growth.
Left:
||||
Year-over-year operating income growth rate
Latest
-240.37%
↓ 836% below average
Average (39q)
-25.68%
Historical baseline
Range
High:273.51%
Low:-721.40%
CAGR
+12.5%
Consistent expansion
| Period | Value |
|---|---|
| Q3 2025 | -240.37% |
| Q2 2025 | 132.11% |
| Q1 2025 | -399.91% |
| Q4 2024 | 72.42% |
| Q3 2024 | -721.40% |
| Q2 2024 | -96.43% |
| Q1 2024 | 270.58% |
| Q4 2023 | -53.88% |
| Q3 2023 | 25.70% |
| Q2 2023 | 23.76% |
| Q1 2023 | -14.33% |
| Q4 2022 | -2.14% |
| Q3 2022 | 20.53% |
| Q2 2022 | -21.84% |
| Q1 2022 | 22.72% |
| Q4 2021 | 0.21% |
| Q3 2021 | -71.35% |
| Q2 2021 | 60.72% |
| Q1 2021 | 13.34% |
| Q4 2020 | -18.64% |
| Q3 2020 | -162.36% |
| Q2 2020 | 273.51% |
| Q1 2020 | -26.26% |
| Q4 2019 | 10.35% |
| Q3 2019 | -18.93% |
| Q2 2019 | -163.61% |
| Q1 2019 | 243.33% |
| Q4 2018 | -19.95% |
| Q3 2018 | -8.78% |
| Q2 2018 | 0.88% |
| Q1 2018 | -21.19% |
| Q4 2017 | 15.39% |
| Q3 2017 | -4.76% |
| Q2 2017 | -6.78% |
| Q1 2017 | -39.62% |
| Q4 2016 | -65.34% |
| Q3 2016 | -23.59% |
| Q2 2016 | 3.31% |
| Q1 2016 | -12.00% |
| Q4 2015 | -2.44% |